| 1. |
- Barausse, Enrico, et al.
(author)
-
Prospects for fundamental physics with LISA
- 2020
-
In: General Relativity and Gravitation. - : SPRINGER/PLENUM PUBLISHERS. - 0001-7701 .- 1572-9532. ; 52:8
-
Journal article (other academic/artistic)abstract
- In this paper, which is of programmatic rather than quantitative nature, we aim to further delineate and sharpen the future potential of the LISA mission in the area of fundamental physics. Given the very broad range of topics that might be relevant to LISA,we present here a sample of what we view as particularly promising fundamental physics directions. We organize these directions through a "science-first" approach that allows us to classify how LISA data can inform theoretical physics in a variety of areas. For each of these theoretical physics classes, we identify the sources that are currently expected to provide the principal contribution to our knowledge, and the areas that need further development. The classification presented here should not be thought of as cast in stone, but rather as a fluid framework that is amenable to change with the flow of new insights in theoretical physics.
|
|
| 2. |
- Pilotto, A., et al.
(author)
-
Steroid-Responsive Encephalitis in Coronavirus Disease 2019
- 2020
-
In: Annals of Neurology. - : Wiley. - 0364-5134 .- 1531-8249. ; 88:2, s. 423-427
-
Journal article (peer-reviewed)abstract
- Coronavirus disease 2019 (COVID-19) infection has the potential for targeting the central nervous system, and several neurological symptoms have been described in patients with severe respiratory distress. Here, we described the case of a 60-year-old patient with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection but only mild respiratory abnormalities who developed an akinetic mutism attributable to encephalitis. Magnetic resonance imaging was negative, whereas electroencephalography showed generalized theta slowing. Cerebrospinal fluid analyses during the acute stage were negative for SARS-CoV-2, positive for pleocytosis and hyperproteinorrachia, and showed increased interleukin-8 and tumor necrosis factor-alpha concentrations. Other infectious or autoimmune disorders were excluded. A progressive clinical improvement along with a reduction of cerebrospinal fluid parameters was observed after high-dose steroid treatment, thus arguing for an inflammatory-mediated brain involvement related to COVID-19. ANN NEUROL 2020
|
|
| 3. |
- Artesani, A., et al.
(author)
-
Monitoring metal ion leaching in oil-ZnO paint systems with a paramagnetic probe
- 2019
-
In: Microchemical Journal. - : Elsevier BV. - 0026-265X. ; 151
-
Journal article (peer-reviewed)abstract
- Zinc oxide (ZnO), used as a pigment since the 19th C., is highly reactive when mixed with drying oils. Indeed, the combination of metal-based pigments and drying oils may react to form metal complexes in paint, which may lead to the aggregation of metal carboxylates or soaps. Whereas the mechanism and chemistry behind metal soap formation has been studied in depth, little research has focused on the changes that affect the inorganic pigment particles. In this work, we concentrate on the first phase of these reactions and monitor the evolution of an oil-ZnO paint system through Electron Paramagnetic Resonance (EPR) spectroscopy. By employing CuII as a paramagnetic probe, the progression of metal ion leaching from ZnO is followed through the switching of CuII from a silent tetrahedral coordination in ZnO bulk to an EPR active pseudo-octahedral coordination. Complementarily, the effective concentration of dissolved or extracted Zn and Cu is quantified through Inductively Coupled Plasma-Optical Emission Spectrometry (ICP-OES). The experiment probes the spontaneous metal ion release in oil-based paint films and demonstrates that the kinetics of this phenomenon proceeds with a very steep increase in the first hours after mixing. This is followed by the saturation of the grow rate after a few days that we ascribe to the passivation of the ZnO pigment surface by carboxylate groups, which hinders the further leaching of metal ions, leading to a steady-state before the complete hardening or oxidation of the paint film. © 2019
|
|
| 5. |
- Massara, Paraskevi, et al.
(author)
-
Nordic dietary patterns and cardiometabolic outcomes : a systematic review and meta-analysis of prospective cohort studies and randomised controlled trials
- 2022
-
In: Diabetologia. - : Springer. - 0012-186X .- 1432-0428. ; 65:12, s. 2011-2031
-
Journal article (peer-reviewed)abstract
- AIMS/HYPOTHESIS: Nordic dietary patterns that are high in healthy traditional Nordic foods may have a role in the prevention and management of diabetes. To inform the update of the EASD clinical practice guidelines for nutrition therapy, we conducted a systematic review and meta-analysis of Nordic dietary patterns and cardiometabolic outcomes.METHODS: We searched MEDLINE, EMBASE and The Cochrane Library from inception to 9 March 2021. We included prospective cohort studies and RCTs with a follow-up of ≥1 year and ≥3 weeks, respectively. Two independent reviewers extracted relevant data and assessed the risk of bias (Newcastle-Ottawa Scale and Cochrane risk of bias tool). The primary outcome was total CVD incidence in the prospective cohort studies and LDL-cholesterol in the RCTs. Secondary outcomes in the prospective cohort studies were CVD mortality, CHD incidence and mortality, stroke incidence and mortality, and type 2 diabetes incidence; in the RCTs, secondary outcomes were other established lipid targets (non-HDL-cholesterol, apolipoprotein B, HDL-cholesterol, triglycerides), markers of glycaemic control (HbA1c, fasting glucose, fasting insulin), adiposity (body weight, BMI, waist circumference) and inflammation (C-reactive protein), and blood pressure (systolic and diastolic blood pressure). The Grading of Recommendations, Assessment, Development and Evaluation (GRADE) approach was used to assess the certainty of the evidence.RESULTS: We included 15 unique prospective cohort studies (n=1,057,176, with 41,708 cardiovascular events and 13,121 diabetes cases) of people with diabetes for the assessment of cardiovascular outcomes or people without diabetes for the assessment of diabetes incidence, and six RCTs (n=717) in people with one or more risk factor for diabetes. In the prospective cohort studies, higher adherence to Nordic dietary patterns was associated with 'small important' reductions in the primary outcome, total CVD incidence (RR for highest vs lowest adherence: 0.93 [95% CI 0.88, 0.99], p=0.01; substantial heterogeneity: I2=88%, pQ<0.001), and similar or greater reductions in the secondary outcomes of CVD mortality and incidence of CHD, stroke and type 2 diabetes (p<0.05). Inverse dose-response gradients were seen for total CVD incidence, CVD mortality and incidence of CHD, stroke and type 2 diabetes (p<0.05). No studies assessed CHD or stroke mortality. In the RCTs, there were small important reductions in LDL-cholesterol (mean difference [MD] -0.26 mmol/l [95% CI -0.52, -0.00], pMD=0.05; substantial heterogeneity: I2=89%, pQ<0.01), and 'small important' or greater reductions in the secondary outcomes of non-HDL-cholesterol, apolipoprotein B, insulin, body weight, BMI and systolic blood pressure (p<0.05). For the other outcomes there were 'trivial' reductions or no effect. The certainty of the evidence was low for total CVD incidence and LDL-cholesterol; moderate to high for CVD mortality, established lipid targets, adiposity markers, glycaemic control, blood pressure and inflammation; and low for all other outcomes, with evidence being downgraded mainly because of imprecision and inconsistency.CONCLUSIONS/INTERPRETATION: Adherence to Nordic dietary patterns is associated with generally small important reductions in the risk of major CVD outcomes and diabetes, which are supported by similar reductions in LDL-cholesterol and other intermediate cardiometabolic risk factors. The available evidence provides a generally good indication of the likely benefits of Nordic dietary patterns in people with or at risk for diabetes.REGISTRATION: ClinicalTrials.gov NCT04094194.
|
|
